Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -97.92% is 97% below its 5-year average of -49.64%, near the low end of its 5-year range (-108.87%–-27.72%).
As of the fiscal period ended Tuesday, June 30, 2026. 21.99% below its 12-month average of -80.27%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -97.92%.
RETURN ON EQUITY (ROE)
-97.92%
RETURN ON EQUITY (ROE) AVG TTM
-80.27%
RETURN ON EQUITY (ROE) AVG 3Y
-58.69%
RETURN ON EQUITY (ROE) AVG 5Y
-49.64%
RETURN ON EQUITY (ROE) AVG 10Y
-60.97%
RETURN ON EQUITY (ROE) AVG 15Y
-74.14%
RETURN ON EQUITY (ROE) AVG 20Y
-75.06%
CURRENT VS TTM AVG
-21.99%
CURRENT VS 3Y AVG
-66.85%
CURRENT VS 5Y AVG
-97.25%
CURRENT VS 10Y AVG
-60.60%
CURRENT VS 15Y AVG
-32.08%
CURRENT VS 20Y AVG
-30.46%
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
-137.67%
vs the sector median at left
DiaMedica Therapeutics Inc.
Market Cap
$444.98M
Return on Equity (ROE)
-97.92%
TTM Avg
-80.27%
3Y Avg
-58.69%
5Y Avg
-49.64%
Market Cap
$444.69M
Return on Equity (ROE)
-16.43%
TTM Avg
-26.04%
3Y Avg
-38.16%
5Y Avg
-45.00%
Market Cap
$446.29M
Return on Equity (ROE)
-160.85%
TTM Avg
-225.75%
3Y Avg
-186.61%
5Y Avg
-129.85%
Market Cap
$441.97M
Return on Equity (ROE)
-52.56%
TTM Avg
-31.09%
3Y Avg
-101.75%
5Y Avg
-86.54%
Market Cap
$435.38M
Return on Equity (ROE)
-0.01%
TTM Avg
-61.70%
3Y Avg
-96.25%
5Y Avg
-81.28%
Market Cap
$432.39M
Return on Equity (ROE)
-38.32%
TTM Avg
-35.34%
3Y Avg
12.60%
5Y Avg
10.50%
Market Cap
$430.17M
Return on Equity (ROE)
-70.24%
TTM Avg
-381.56%
3Y Avg
-217.03%
5Y Avg
-155.40%
Market Cap
$457.04M
Return on Equity (ROE)
89.43%
TTM Avg
81.07%
3Y Avg
67.39%
5Y Avg
61.90%
Market Cap
$428.59M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | $444.98M | -97.92% | -80.27% | -58.69% | -49.64% |
| Ovid Therapeutics Inc. (OVID)vs › | $444.69M | -16.43% | -26.04% | -38.16% | -45.00% |
| NeuroPace, Inc. (NPCE)vs › | $446.29M | -160.85% | -225.75% | -186.61% | -129.85% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $441.97M | -52.56% | -31.09% | -101.75% | -86.54% |
| Assembly Biosciences, Inc. (ASMB)vs › | $435.38M | -0.01% | -61.70% | -96.25% | -81.28% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $432.39M | -38.32% | -35.34% | 12.60% | 10.50% |
| Editas Medicine, Inc. (EDIT)vs › | $430.17M | -70.24% | -381.56% | -217.03% | -155.40% |
| NRC Health (NRC)vs › | $457.04M | 89.43% | 81.07% | 67.39% | 61.90% |
| NeoGenomics, Inc. (NEO)vs › | $428.59M | -6.60% | -10.82% | -11.36% | -7.59% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $421.92M | -1721.80% | -73.40% | -45.77% | -18.46% |
ROE
-97.9%
ROA
-83.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -97.92% |
| 2026-03-31 | -74.31% |
| 2025-12-31 | -58.39% |
| 2025-09-30 | -61.85% |
| 2025-06-30 | -108.87% |
| 2025-03-31 | -79.52% |
| 2024-12-31 | -60.03% |
| 2024-09-30 | -45.25% |
| 2024-06-30 | -37.26% |
| 2024-03-31 | -41.55% |
| 2023-12-31 | -37.96% |
| 2023-09-30 | -32.31% |
| 2023-06-30 | -27.72% |
| 2023-03-31 | -57.14% |
| 2022-12-31 | -42.97% |
| 2022-09-30 | -37.55% |
| 2022-06-30 | -35.96% |
| 2022-03-31 | -33.06% |
| 2021-12-31 | -30.87% |
| 2021-09-30 | -30.93% |
| 2021-06-30 | -70.33% |
| 2021-03-31 | -58.28% |
| 2020-12-31 | -47.25% |
| 2020-09-30 | -35.53% |
| 2020-06-30 | -87.18% |
| 2020-03-31 | -73.72% |
| 2019-12-31 | -139.81% |
| 2019-09-30 | -95.16% |
| 2019-06-30 | -62.48% |
| 2019-03-31 | -60.44% |
| 2018-12-31 | -33.68% |
| 2018-09-30 | -421.02% |
| 2018-06-30 | -411.19% |
| 2018-03-31 | -74.64% |
| 2017-12-31 | -533.17% |
| 2017-06-30 | -510.55% |
| 2016-12-31 | -179.46% |
| 2016-09-30 | -142.14% |
| 2013-12-31 | -535.97% |
| 2013-06-30 | -657.46% |
| 2013-03-31 | -302.37% |
| 2012-12-31 | -438.96% |
| 2012-09-30 | -172.50% |
| 2012-06-30 | -144.10% |
| 2012-03-31 | -155.26% |
| 2011-12-31 | -114.25% |
| 2011-09-30 | -90.82% |
| 2011-06-30 | -97.07% |
| 2011-03-31 | -70.17% |
| 2010-12-31 | -48.07% |
| 2010-09-30 | -39.27% |
| 2010-06-30 | -28.90% |
| 2010-03-31 | -340.58% |
| 2009-12-31 | -217.51% |
| 2009-09-30 | -132.57% |
| 2009-06-30 | -110.65% |
| 2009-03-31 | -110.83% |
| 2008-12-31 | -67.77% |
| 2008-09-30 | -58.47% |
| 2008-06-30 | -58.90% |
| 2008-03-31 | -59.72% |
| 2007-12-31 | -54.94% |
| 2007-09-30 | -39.61% |
| 2007-06-30 | -34.73% |
| 2007-03-31 | -16.11% |
| 2006-12-31 | -117.84% |
| 2006-09-30 | -121.86% |
| 2005-12-31 | -40.68% |
